	US 11,938,158 B2
	Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
Eric Michael Schott, West Roxbury, MA (US); Maria Juliana Soto-Giron, Cambridge, MA (US); and Gerardo V. Toledo, Hopkinton, MA (US)
Assigned to Solarea Bio, Inc., Cambridge, MA (US)
Filed by Solarea Bio, Inc., Cambridge, MA (US)
Filed on Mar. 9, 2023, as Appl. No. 18/181,495.
Application 18/181,495 is a continuation of application No. PCT/US2022/080362, filed on Nov. 22, 2022.
Claims priority of provisional application 63/382,666, filed on Nov. 7, 2022.
Claims priority of provisional application 63/282,155, filed on Nov. 22, 2021.
Prior Publication US 2023/0346859 A1, Nov. 2, 2023
Int. Cl. A61K 35/741 (2015.01); A61K 9/00 (2006.01); A61K 31/122 (2006.01); A61K 31/355 (2006.01); A61K 31/375 (2006.01); A61K 31/593 (2006.01); A61K 35/744 (2015.01); A61K 35/747 (2015.01); A61K 36/064 (2006.01); A61K 47/26 (2006.01); A61K 47/46 (2006.01); A61P 15/12 (2006.01)

CPC A61K 35/747 (2013.01) [A61K 9/0056 (2013.01); A61K 31/122 (2013.01); A61K 31/355 (2013.01); A61K 31/375 (2013.01); A61K 31/593 (2013.01); A61K 35/744 (2013.01); A61K 36/064 (2013.01); A61K 47/26 (2013.01); A61K 47/46 (2013.01); A61P 15/12 (2018.01)]

18 Claims

1. A dietary supplement comprising a combination of four heterologous microbes comprising Lactobacillus brevis, Lactobacillus plantarum, Leuconostoc mesenteroides, and Pichia kudriavzevii, wherein the heterologous microbes are co-formulated as a synthetic microbial consortium comprising about 1.0×10⁸to about 1.0×10¹²CFU of each of the heterologous microbes, wherein the Pichia kudriavzevii comprises a fungal ITS sequence having at least 97% identity to SEQ ID NO: 102 at the fungal ITS sequence, formulated in an amount effective for lessening a decrease in, maintaining, or improving bone health in a human subject, wherein the dietary supplement is formulated for oral delivery.